|
Jan 4
|
Better Buy: Novo Nordisk vs. AstraZeneca
|
|
Jan 3
|
From Davids to Goliaths: the GLP-1RA gold rush
|
|
Jan 2
|
Don't Buy Weight-Loss Medication From Unauthorized Sources, UK Health Agency Warns About Risks
|
|
Jan 2
|
Zepbound will dominate obesity market following SURMOUNT-5 results, says analyst
|
|
Jan 2
|
US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report
|
|
Jan 2
|
Should You Buy the Dip in Novo Nordisk Stock Right Now?
|
|
Jan 2
|
Tirzepatide outpacing Wegovy in the obesity space
|
|
Jan 2
|
Weight loss drugs are changing the game, Eli Lilly exec says — but many still can't get them
|
|
Jan 1
|
Drug-Trial Results Could Shake Up Pharma Stocks in 2025. Watch Eli Lilly, Pfizer, and More.
|
|
Dec 31
|
Historical Trends Warrant a Closer Look at Novo Nordisk (NVO) Call Options
|
|
Dec 31
|
GLP-1 questions emerge for 2025
|
|
Dec 31
|
Novo Nordisk A/S (NVO): A Bull Case Theory
|
|
Dec 31
|
Lilly and Novo Went Head-to-Head Over Weight-Loss Drugs in 2024. There’s a Clear Winner.
|
|
Dec 30
|
Is Novo Nordisk A/S (NVO) the Best Pharma Dividend Stock to Buy In 2024?
|
|
Dec 30
|
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
|
|
Dec 29
|
3 Stocks That Could Be Monster Winners in 2025
|
|
Oct 11
|
Here’s What Dragged Novo Nordisk A/S (NVO) in Q3
|
|
Oct 11
|
Wegovy maker Novo Nordisk bets big on talent, AI partnerships in India
|
|
Oct 11
|
Warning: This Skyrocketing Stock Has a Hidden Risk
|
|
Oct 10
|
WeightWatchers stock soars, but its cheap Wegovy knockoff 'is not a sustainable long-term business model'
|